Heterologous Prime-boost Immunization Induces Protection Against Dengue Virus Infection in Cynomolgus Macaques

Currently licensed dengue vaccines do not induce long-term protection in children without previous exposure to dengue viruses in nature. These vaccines are based on selected attenuated strains of the four dengue serotypes and employed in combination for two or three consecutive doses. In our search for a better dengue vaccine candidate, live attenuated strains were followed by non-infectious virus-like particles or the plasmids that generate these particles upon injection into the body. This heterologous prime-boost immunization induced elevated levels of virus-specific antibodies and helped to prevent dengue virus infection in a high proportion of vaccinated macaques. In macaques that remained susceptible to dengue virus, distinct mechanisms were found to account for the immunization failures, providing a better understanding of vaccine actions. Additional studies in humans in the future may help to establish whether this combination approach represents a more effective means of preventing dengue by vaccination.

References

Rivera L, Biswal S, Saez-Llorens X, Reynales H, Lopez-Medina E, Borja-Tabora C . Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003). Clin Infect Dis. 2021; 75(1):107-117. PMC: 9402653. DOI: 10.1093/cid/ciab864. View

Laydon D, Dorigatti I, Hinsley W, Nedjati-Gilani G, Coudeville L, Ferguson N . Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data. Elife. 2021; 10. PMC: 8321579. DOI: 10.7554/eLife.65131. View

Auerswald H, Klepsch L, Schreiber S, Hulsemann J, Franzke K, Kann S . The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study. Viruses. 2019; 11(4). PMC: 6521013. DOI: 10.3390/v11040304. View

Robinson L, Tharakaraman K, Rowley K, Costa V, Chan K, Wong Y . Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Cell. 2015; 162(3):493-504. PMC: 4758460. DOI: 10.1016/j.cell.2015.06.057. View

Yang Y, Meng Y, Halloran M, Longini Jr I . Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine. Clin Infect Dis. 2017; 66(2):178-184. PMC: 5850009. DOI: 10.1093/cid/cix766. View

Zhang S, Liang M, Gu W, Li C, Miao F, Wang X . Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virol J. 2011; 8:333. PMC: 3144018. DOI: 10.1186/1743-422X-8-333. View

Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384(9951):1358-65. DOI: 10.1016/S0140-6736(14)61060-6. View

Butrapet S, Huang C, Pierro D, Bhamarapravati N, Gubler D, Kinney R . Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3. J Virol. 2000; 74(7):3011-9. PMC: 111799. DOI: 10.1128/jvi.74.7.3011-3019.2000. View

Junjhon J, Edwards T, Utaipat U, Bowman V, Holdaway H, Zhang W . Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J Virol. 2010; 84(16):8353-8. PMC: 2916513. DOI: 10.1128/JVI.00696-10. View

10.

Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, OBrien K, Vannice K . Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. 2018; 19(1):e31-e38. DOI: 10.1016/S1473-3099(18)30494-8. View

11.

Katzelnick L, Montoya M, Gresh L, Balmaseda A, Harris E . Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci U S A. 2016; 113(3):728-33. PMC: 4725482. DOI: 10.1073/pnas.1522136113. View

12.

Zhou Y, Austin S, Fremont D, Yount B, Huynh J, de Silva A . The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology. 2013; 439(1):57-64. PMC: 3608513. DOI: 10.1016/j.virol.2013.01.022. View

13.

Fibriansah G, Tan J, Smith S, de Alwis A, Ng T, Kostyuchenko V . A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med. 2014; 6(3):358-71. PMC: 3958310. DOI: 10.1002/emmm.201303404. View

14.

Crill W, Hughes H, Delorey M, Chang G . Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009; 4(4):e4991. PMC: 2659788. DOI: 10.1371/journal.pone.0004991. View

15.

Sirivichayakul C, Sabchareon A, Limkittikul K, Yoksan S . Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand. Virol J. 2014; 11:48. PMC: 3975240. DOI: 10.1186/1743-422X-11-48. View

16.

Keelapang P, Supasa P, Sriburi R, Puttikhunt C, Cardosa J, Kasinrerk W . A group of infection-enhancing and focus size-reducing monoclonal antibodies recognized an 'a and c' strands epitope in the pr domain of Dengue Virus prM. Virus Res. 2022; 323:199015. PMC: 9742851. DOI: 10.1016/j.virusres.2022.199015. View

17.

Angelo M, Grifoni A, ORourke P, Sidney J, Paul S, Peters B . Human CD4 T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. J Virol. 2016; 91(5). PMC: 5309943. DOI: 10.1128/JVI.02147-16. View

18.

Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A . Corrigendum: A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015; 16(7):785. DOI: 10.1038/ni0715-785a. View

19.

Ketloy C, Keelapang P, Prompetchara E, Suphatrakul A, Puttikhunt C, Kasinrerk W . Strategies to improve the immunogenicity of prM+E dengue virus type-2 DNA vaccine. Asian Pac J Allergy Immunol. 2016; 35(1):11-19. DOI: 10.12932/AP0728. View

20.

Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, Jalah R . Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine. 2010; 28(30):4827-36. PMC: 2932451. DOI: 10.1016/j.vaccine.2010.04.064. View